Jan Maxwell Nørgaard

Jan Maxwell Nørgaard

Auto-generated profile, based on publicly available information

Jan Maxwell Nørgaard

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
BMBruno C. Medeiros
Bruno C. Medeiros
HSHenrik Sengeløv
Henrik Sengeløv
MNMette Nørgaard
Mette Nørgaard
MAMette Klarskov Andersen
Mette Klarskov Andersen
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
Purpose: Secondary and therapy-related acute myeloid leukemia (sAML and tAML, respectively) remain therapeutic challenges. Still, it is unclear whether their inferior outcome compared with de novo acute myeloid leukemia (AML) varies as a result of previous hematologic disease or can be explained by differences in karyotype and/or age. Patients and Methods: In a Danish national population-based study of 3,055 unselected patients with AML diagnosed from 2000 to 2013, we compared the frequencies and characteristics of tAML, myelodysplastic syndrome (MDS) -sAML, and non-MDS-sAML (chronic myelomonocytic leukemia and myeloproliferative neoplasia) versus de novo AML. Limited to intensive therapy patients, we compared chance of complete remission by logistic regression analysis and used a pseudo-value approach to compare relative risk (RR) of death at 90 days, 1 year, and 3 years, overall and stratified by age and karyotype. Results were given crude and adjusted with 95% CIs. Results: Overall, frequencies of sAML and tAML were 19.8% and 6.6%, respectively. sAML, but not tAML, was associated with low likelihood of receiving intensive treatment. Among intensive therapy patients (n = 1,567), antecedent myeloid disorder or prior cytotoxic exposure was associated with decreased complete remission rates and inferior survival (3-year adjusted RR for MDS-sAML, non-MDS-sAML, and tAML: RR, 1.14; 95% CI, 1.02 to 1.32; RR, 1.27; 95% CI, 1.16 to 1.34; and RR, 1.16; 95% CI, 1.03 to 1.32, respectively) compared with de novo AML. Among patients ≥ 60 years old and patients with adverse karyotype, previous MDS or tAML did not impact overall outcomes, whereas non-MDS-sAML was associated with inferior survival across age and cytogenetic risk groups (adverse risk cytogenetics: 1-year adjusted RR, 1.47; 95% CI, 1.23 to 1.76; patients ≥ 60 years old: 1-year adjusted RR, 1.31; 95% CI, 1.06 to 1.61). Conclusion: Our results support that de novo AML, sAML, and tAML are biologically and prognostically distinct subtypes of AML. Patients with non-MDS-sAML have dismal outcomes, independent of age and cytogenetics. Previous myeloid disorder, age, and cytogenetics are crucial determinants of outcomes and should be integrated in treatment recommendations for these patients.

5 August 2014 in Leukemia
Verified
Journal Article
Closed access
PDF file
LØL S G Østgård
L S G Østgård
JNJ M Nørgaard
J M Nørgaard
HSH Sengeløv
H Sengeløv
MSMarianne Tang Severinsen
Marianne Tang Severinsen
LFL S Friis
L S Friis
MNM Nørgaard
M Nørgaard

1 September 2013 in Clinical Epidemiology
Verified
Journal Article
Open access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
MNMette Nørgaard
Mette Nørgaard
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
MSMarianne Tang Severinsen
Marianne Tang Severinsen
HSHenrik Sengeløv
Henrik Sengeløv
ONOve Juul Nielsen
Ove Juul Nielsen
Peer reviewed article authored by (Østgård LSG, Nørgaard JM, Severinsen MT, Sengeløv H, Friis L, Jensen MK, Nielsen OJ, Nørgaard M). Read article or submit your manuscript for publishing.

12 August 2010 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
EKEigil Kjeldsen
Eigil Kjeldsen
MHMette Skov Holm
Mette Skov Holm
PBPeter De Nully Brown
Peter De Nully Brown
BPBjarne Bach Pedersen
Bjarne Bach Pedersen
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard

30 June 2011 in Haematologica
Verified
Journal Article
Closed access
LML. Mollgard
L. Mollgard
LSL. Saft
L. Saft
MTM. B. Treppendahl
M. B. Treppendahl
IDI. Dybedal
I. Dybedal
JNJ. M. Norgaard
J. M. Norgaard
ELE. H. Lindberg
E. H. Lindberg
Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybridization for del(5q31). Twenty-eight patients at diagnosis or with relapsed disease and not eligible for standard therapy (16 with acute myeloid leukemia, 12 with intermediate-risk 2 or high-risk myelodysplastic syndrome) were enrolled in this prospective phase II multicenter trial and treated with lenalidomide up to 30 mg daily for 16 weeks. Three patients had isolated del(5q), six had del(5q) plus one additional aberration, 14 had del(5q) and a complex karyotype, four had monosomy 5, and one had del(5q) identified by fluorescence in situ hybridization only. Major and minor cytogenetic responses, assessed by fluorescence in situ hybridization, were achieved in 5/26 (19%) and 2/26 (8%) patients, respectively, who received one or more dose of lenalidomide, while two patients achieved only a bone marrow response. Nine of all 26 patients (35%) and nine of the ten who completed the 16 weeks of trial responded to treatment. Using the International Working Group criteria for acute myeloid leukemia and myelodysplastic syndrome the overall response rate in treated patients with acute myeloid leukemia was 20% (3/15), while that for patients with myelodysplastic syndrome was 36% (4/11). Seven patients stopped therapy due to progressive disease and nine because of complications, most of which were disease-related. Response rates were similar in patients with isolated del(5q) and in those with additional aberrations. Interestingly, patients with TP53 mutations responded less well than those without mutations (2/13 versus 5/9, respectively; P=0.047). No responses were observed among 11 cases with deleterious TP53 mutations. Our data support a role for higher doses of lenalidomide in poor prognosis patients with myelodysplastic syndrome and acute myeloid leukemia with deletion 5q. (Clinicaltrials.gov identifier NCT00761449).

10 November 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
MNMette Nørgaard
Mette Nørgaard
BMBruno C. Medeiros
Bruno C. Medeiros
LFLone Smidstrup Friis
Lone Smidstrup Friis
CSClaudia Schoellkopf
Claudia Schoellkopf
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
Purpose: Previous US studies have shown that socioeconomic status (SES) affects survival in acute myeloid leukemia (AML). However, no large study has investigated the association between education or income and clinical characteristics, treatment, and outcome in AML. Methods: To investigate the effects of education and income in a tax-supported health care system, we conducted a population-based study using individual-level SES and clinical data on all Danish patients with AML (2000 to 2014). We compared treatment intensity, allogeneic transplantation, and response rates by education and income level using logistic regression (odds ratios). We used Cox regression (hazard ratios [HRs]) to compare survival, adjusting for age, sex, SES, and clinical prognostic markers. Results: Of 2,992 patients, 1,588 (53.1%) received intensive chemotherapy. Compared with low-education patients, highly educated patients more often received allogeneic transplantation (16.3% v 8.7%). In intensively treated patients younger than 60 years of age, increased mortality was observed in those with lower and medium education (1-year survival, 66.7%; adjusted HR, 1.47; 95% CI, 1.11 to 1.93; and 1-year survival, 67.6%; adjusted HR, 1.55; CI, 1.21 to 1.98, respectively) compared with higher education (1-year survival, 76.9%). Over the study period, 5-year survival improvements were limited to high-education patients (from 39% to 58%), increasing the survival gap between groups. In older patients, low-education patients received less intensive therapy (30% v 48%; adjusted odds ratio, 0.65; CI, 0.44 to 0.98) compared with high-education patients; however, remission rates and survival were not affected in those intensively treated. Income was not associated with therapy intensity, likelihood of complete remission, or survival (high income: adjusted HR, 1.0; medium income: adjusted HR, 0.96; 95% CI, 0.82 to 1.12; low income: adjusted HR, 1.06; CI, .88 to 1.27). Conclusion: In a universal health care system, education level, but not income, affects transplantation rates and survival in younger patients with AML. Importantly, recent survival improvement has exclusively benefitted highly educated patients.